ANAB: A Royalty Stub Discounting a Courtroom, Not a Pipeline — WATCH at $46.09

Setup

AnaptysBio is no longer a clinical-stage biotech. Since the April 20, 2026 spin-off of its R&D engine into First Tracks Biotherapeutics (Nasdaq: TRAX), ANAB has operated as a virtual royalty-management company with fewer than ten employees, earning tiered royalties on GSK's Jemperli plus a potential second stream from imsidolimab (Vanda's Quimilza), with a share repurchase plan as the residual capital-allocation lever (stockanalysis.com transcript, tickeron forecast). That makes the equity a levered claim on one GSK franchise, a Sagard funding structure that must be paid down, and a Delaware court (flash.stocksentinel.ai). At $46.09, the stock is down roughly 18% in 30 days from about $55.20, still up more than 50% YTD — a stub that round-tripped its latest catalyst (tickeron.com).

Evidence & Data

The technical stack is unambiguous: RSI 44.2, MACD barely positive at 0.025, 5-day momentum +5.41% against 20-day momentum -11.53%, and a bearish SMA trend — a counter-trend bounce inside a downtrend. News sentiment is negative at -0.1855. Options flow shows no whale positioning, so the tape offers no hedging signal either way. The engine reads Neutral (49/100, calibrated win probability 39%), and this name sits outside any qualifying T+30 cohort.

Consensus vs. this thesis — the variant perception. The street is at Strong Buy with a $78.06 target, +69% above the current print (tickeron.com). We disagree with that target as it stands. The mid-October FDA accelerated approval of Jemperli in rectal cancer briefly lifted shares — and the market promptly sold it back down into the mid-$40s (tickeron.com). When a stock can't hold a genuinely positive regulatory catalyst, the message is that holders are monetizing news into an unresolvable legal overhang. Our read: consensus is pricing a favorable Tesaro/GSK litigation outcome as if it were already delivered (tickeron forecast); we treat it as a coin-flip we cannot underwrite, and we suspect the market is under-pricing the discount a royalty stub deserves while its defining revenue stream is contested (flash.stocksentinel.ai).

Macro. The tape is fragile: QL's own coverage logged VIX at 17.1 into earnings week (QuantLogix CHRN note), and recent graded events (OKE and CRM invalidations, AMD's WATCH grading at -28.84%) show momentum names breaking hard. A contested, sub-$2B royalty stub with binary legal risk is exactly the profile that rotation punishes when vol ticks up; macro argues for patience, not anticipation.

Scenario Analysis

EV = 0.25×$65 + 0.50×$46 + 0.25×$33 = $16.25 + $23.00 + $8.25 = $47.50, +3.1% vs. current $46.09 — positive but below the +5% per-call alpha bar, and inside the noise band of a name whose 30-day realized move was -18%. That arithmetic, not timidity, is why this is a WATCH: the engine's own calibration (BULLISH verdicts have averaged just +1.6%, 9/24) says bullish calls against a Neutral engine read don't clear the bar.

Catalysts & Risks

(stockanalysis.com, tickeron forecast, flash.stocksentinel.ai)

What Changes Our Mind

This WATCH is falsifiable on three specific triggers. First, a close above $52.00 within 30 trading days — without litigation news — tells us the post-FDA supply was absorbed and flips the call bullish; a close above $78.06 within 12 months would outright refute our variant view and we would say so. Second, a close below $40.00 within 30 trading days confirms breakdown and flips us bearish. Third, any headline resolution of the Tesaro dispute — settlement or ruling — forces immediate re-underwriting, because it collapses the base case into one of the tails. Until one of those prints, the honest position is that ANAB is a fairly-priced coin flip wearing a Strong Buy sticker — educational commentary, not investment advice.